(19)
(11) EP 3 256 147 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.10.2020 Bulletin 2020/43

(45) Mention of the grant of the patent:
05.08.2020 Bulletin 2020/32

(21) Application number: 16703658.1

(22) Date of filing: 15.01.2016
(51) International Patent Classification (IPC): 
A61K 38/18(2006.01)
 A61K 47/12(2006.01)
(86) International application number:
PCT/US2016/013564
(87) International publication number:
WO 2016/115442 (21.07.2016 Gazette 2016/29)

(54)

THERAPEUTIC PROTEIN FORMULATIONS

THERAPEUTISCHE PROTEINFORMULIERUNGEN

FORMULATIONS DE PROTÉINES THÉRAPEUTIQUES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.01.2015 US 201562104804 P

(43) Date of publication of application:
20.12.2017 Bulletin 2017/51

(60) Divisional application:
20189324.5
20189367.4

(73) Proprietor: Gloriana Therapeutics, Inc.
Rhode Island, RI 02885 (US)

(72) Inventor:
  • DIMITROVA, Mariana
    Medford, Massachusetts 02155 (US)

(74) Representative: Grund, Martin 
Grund Intellectual Property Group Patentanwalt und Solicitor PartG mbB Postfach 44 05 16
80754 München
80754 München (DE)


(56) References cited: : 
WO-A1-02/052433
WO-A1-2012/138958
WO-A2-02/078730
 WO-A1-2008/137574
WO-A2-00/01815
WO-A2-2007/103182
   
  • SYDNEY O UGWU ET AL: "The effect of buffers on protein conformational stability", PHARMACEUTICAL TECHNOLOGY, vol. 28, no. 3, 1 March 2004 (2004-03-01), page 86, XP055259995, US ISSN: 1543-2521
  • "Data Sheet Growth AGGPGSRARA AGARGCRLRS QLVPVRALGL GHRSDELVRF RFCSGSCRRA RSPHDLSLAS LLGAGALRPP PGSRPVSQPC CRPTRYEAVS FMDVNSTWRT VDRLSATACG CLG", , 3 January 2011 (2011-01-03), XP055263182, Retrieved from the Internet: URL:http://www.cellgs.com/Downloads/1002/d atasheet_artemin_human.pdf [retrieved on 2016-04-06]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).